Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Study of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma, and Other GD2(+) Solid Tumors

NCT03860207 is registered in ClinicalTrials.gov with Y-mAbs Therapeutics as lead sponsor.

NCT NCT03860207
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03860207 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Study of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma, and Other GD2(+) Solid Tumors
Lead sponsor
Y-mAbs Therapeutics
Phase
Phase 1/2
Overall status
Terminated
Start date
February 22, 2019
Completion date
October 20, 2021
Enrollment
12 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

neuroblastoma, osteosarcoma, other solid tumor cancers